Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghel, Nazanin, Delgado, Diego Hernan, Lipton, Jeffrey Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552150/
https://www.ncbi.nlm.nih.gov/pubmed/28831263
http://dx.doi.org/10.2147/VHRM.S108874
_version_ 1783256420677844992
author Aghel, Nazanin
Delgado, Diego Hernan
Lipton, Jeffrey Howard
author_facet Aghel, Nazanin
Delgado, Diego Hernan
Lipton, Jeffrey Howard
author_sort Aghel, Nazanin
collection PubMed
description Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular safety of TKIs are discussed. We also propose management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents.
format Online
Article
Text
id pubmed-5552150
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55521502017-08-22 Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance Aghel, Nazanin Delgado, Diego Hernan Lipton, Jeffrey Howard Vasc Health Risk Manag Review Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular safety of TKIs are discussed. We also propose management strategies for cardiovascular surveillance and risk factor modification during treatment with these agents. Dove Medical Press 2017-08-04 /pmc/articles/PMC5552150/ /pubmed/28831263 http://dx.doi.org/10.2147/VHRM.S108874 Text en © 2017 Aghel et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Aghel, Nazanin
Delgado, Diego Hernan
Lipton, Jeffrey Howard
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title_full Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title_fullStr Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title_full_unstemmed Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title_short Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
title_sort cardiovascular toxicities of bcr-abl tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552150/
https://www.ncbi.nlm.nih.gov/pubmed/28831263
http://dx.doi.org/10.2147/VHRM.S108874
work_keys_str_mv AT aghelnazanin cardiovasculartoxicitiesofbcrabltyrosinekinaseinhibitorsinchronicmyeloidleukemiapreventivestrategiesandcardiovascularsurveillance
AT delgadodiegohernan cardiovasculartoxicitiesofbcrabltyrosinekinaseinhibitorsinchronicmyeloidleukemiapreventivestrategiesandcardiovascularsurveillance
AT liptonjeffreyhoward cardiovasculartoxicitiesofbcrabltyrosinekinaseinhibitorsinchronicmyeloidleukemiapreventivestrategiesandcardiovascularsurveillance

Ejemplares similares